Quantifying the Risk of Drug-Induced Pancreatitis With Angiotensin-Converting Enzyme Inhibitors and Statins Using a Large Electronic Medical Record Database.
Journal
Pancreas
ISSN: 1536-4828
Titre abrégé: Pancreas
Pays: United States
ID NLM: 8608542
Informations de publication
Date de publication:
01 09 2021
01 09 2021
Historique:
entrez:
29
10
2021
pubmed:
30
10
2021
medline:
22
3
2022
Statut:
ppublish
Résumé
Quantify the risk of drug-induced pancreatitis (DIP) from angiotensin-converting enzyme inhibitors (ACEis) and 3-hydroxy-3-methyl-glutaryl-CoA reductase inhibitors (statins). Retrospective cohort analysis using IBM Explorys (1999-2019), a pooled, deidentified clinical database of more than 63 million patients across the United States. Odds ratios were calculated to determine the risk of DIP from ACEi, statins, and both medications together. χ2 testing assessed the relationship between age, sex, ethnicity, insurance status, and mortality among patients with DIP from ACEi, statins, or both combined. Acute pancreatitis (AP) was found in 280,740 patients. Odds ratios for ACEi, statins, and both combined were 6.12, 4.97, and 5.72, respectively. Thirty-eight percent of all-cause AP occurs in adults older than 65 years. Acute pancreatitis from ACEi and statins occurs in 49% and 56% of patients older than 65 years, respectively. Men and patients older than 65 years are at higher risk of DIP from ACEi and statins. Patients on Medicaid are at higher risk of DIP from statins, and Asian patients are at highest risk of DIP from ACEi. We found that ACEi and statins increase the odds of DIP. Although ACEis and statins are critical medications for many patients, clinicians should consider using alternatives in patients with AP of unclear etiology.
Identifiants
pubmed: 34714286
doi: 10.1097/MPA.0000000000001895
pii: 00006676-202109000-00012
doi:
Substances chimiques
Angiotensin-Converting Enzyme Inhibitors
0
Hydroxymethylglutaryl-CoA Reductase Inhibitors
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1212-1217Informations de copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Peery AF, Crockett SD, Murphy CC, et al. Burden and cost of gastrointestinal, liver, and pancreatic diseases in the United States: update 2018. Gastroenterology . 2019;156:254–272.e11.
García-Rayado G, Cárdenas-Jaén K, de-Madaria E. Towards evidence-based and personalized care of acute pancreatitis. United European Gastroenterol J . 2020;8:403–409.
Jones MR, Hall OM, Kaye AM, et al. Drug-induced acute pancreatitis: a review. Ochsner J . 2015;15:45–51.
Pellock JM, Wilder BJ, Deaton R, et al. Acute pancreatitis coincident with valproate use: a critical review. Epilepsia . 2002;43:1421–1424.
Kaurich T. Drug-induced acute pancreatitis. Proc (Baylor Univ Med Cent) . 2008;21:77–81.
Nitsche C, Maertin S, Scheiber J, et al. Drug-induced pancreatitis. Curr Gastroenterol Rep . 2012;14:131–138.
Conti Bellocchi MC, Campagnola P, Frulloni L. Drug-induced acute pancreatitis. The Pancreapedia: Exocrine Pancreas Knowledge Base . August 8, 2015. Available at: https://www.pancreapedia.org/reviews/drug-induced-acute-pancreatitis . Accessed March 10, 2019.
Eland IA, van Puijenbroek EP, Sturkenboom MJ, et al. Drug-associated acute pancreatitis: twenty-one years of spontaneous reporting in The Netherlands. Am J Gastroenterol . 1999;94:2417–2422.
Gershon T, Olshaker JS. Acute pancreatitis following lisinopril rechallenge. Am J Emerg Med . 1998;16:523–524.
Marinella MA, Billi JE. Lisinopril therapy associated with acute pancreatitis. West J Med . 1995;163:77–78.
Brown KV, Khan AZ, Paterson IM. Lisinopril-induced acute pancreatitis. J R Army Med Corps . 2007;153:191–192.
Kanbay M, Selcuk H, Yilmaz U, et al. Recurrent acute pancreatitis probably secondary to lisinopril. South Med J . 2006;99:1388–1389.
Maringhini A, Termini A, Patti R, et al. Enalapril-associated acute pancreatitis: recurrence after rechallenge. Am J Gastroenterol . 1997;92:166–167.
Carnovale A, Esposito P, Bassano P, et al. Enalapril-induced acute recurrent pancreatitis. Dig Liver Dis . 2003;35:55–57.
González Ramallo VJ, Muiño Miguez A, Torres Segovia FJ. Necrotizing pancreatitis and enalapril. Eur J Med . 1992;1:123.
Jeandidier N, Klewansky M, Pinget M. Captopril-induced acute pancreatitis. Diabetes Care . 1995;18:410–411.
Kanbay M, Korkmaz M, Yilmaz U, et al. Acute pancreatitis due to ramipril therapy. Postgrad Med J . 2004;80:617–618.
Gallego-Rojo FJ, Gonzalez-Calvin JL, Guilarte J, et al. Perindopril-induced acute pancreatitis. Dig Dis Sci . 1997;42:1789–1791.
Thisted H, Jacobsen J, Munk EM, et al. Statins and the risk of acute pancreatitis: a population-based case-control study. Aliment Pharmacol Ther . 2006;23:185–190.
Johnson JL, Loomis IB. A case of simvastatin-associated pancreatitis and review of statin-associated pancreatitis. Pharmacotherapy . 2006;26:414–422.
Pezzilli R, Ceciliato R, Corinaldesi R, et al. Acute pancreatitis due to simvastatin therapy: increased severity after rechallenge. Dig Liver Dis . 2004;36:639–640.
Ramdani M, Schmitt AM, Liautard J, et al. [Simvastatin-induced acute pancreatitis: two cases]. [Article in French]. Gastroenterol Clin Biol . 1991;15:986.
Chintanaboina J, Gopavaram D. Recurrent acute pancreatitis probably induced by rosuvastatin therapy: a case report. Case Rep Med . 2012;2012:973279.
Lai SW, Lin CL, Liao KF. Rosuvastatin and risk of acute pancreatitis in a population-based case-control study. Int J Cardiol . 2015;187:417–420.
Anagnostopoulos GK, Tsiakos S, Margantinis G, et al. Acute pancreatitis due to pravastatin therapy. JOP . 2003;4:129–132.
Becker C, Hvalic C, Delmore G, et al. [Recurrent acute pancreatitis during pravastatin-therapy]. [Article in German]. Praxis (Bern 1994) . 2006;95:111–116.
Belaïche G, Ley G, Slama JL. [Acute pancreatitis associated with atorvastatine therapy]. [Article in French]. Gastroenterol Clin Biol . 2000;24:471–472.
Singh S, Nautiyal A, Dolan JG. Recurrent acute pancreatitis possibly induced by atorvastatin and rosuvastatin. Is statin induced pancreatitis a class effect? JOP . 2004;5:502–504.
Tysk C, Al-Eryani AY, Shawabkeh AA. Acute pancreatitis induced by fluvastatin therapy. J Clin Gastroenterol . 2002;35:406–408.
de-Madaria E. Statins for the prevention of acute pancreatitis. Am J Gastroenterol . 2017;112:1765–1767.
Explorys team. We unlock the power of BIG DATA to improve healthcare for everyone. Available at: https://www.ibm.com/watson/health/about/ . Accessed March 10, 2019.
Garg A, Hundal J, Strunk A. Overall and subgroup prevalence of Crohn disease among patients with hidradenitis suppurativa: a population-based analysis in the United States. JAMA Dermatol . 2018;154:814–818.
US National Library of Medicine Unified Medical Language System (UMLS) Systematized Nomenclature of Medicine–Clinical Terms (SNOMED CT). Available at: https://www.nlm.nih.gov/research/umls/Snomed/snomed_main.html . Accessed March 10, 2019.
Nelson SJ, Zeng K, Kilbourne J, et al. Normalized names for clinical drugs: RxNorm at 6 years. J Am Med Inform Assoc . 2011;18:441–448.
McDonald CJ, Huff SM, Suico JG, et al. LOINC, a universal standard for identifying laboratory observations: a 5-year update. Clin Chem . 2003;49:624–633.
Glover M, Mansoor E, Panhwar M, et al. Epidemiology of colorectal cancer in average risk adults 20–39 years of age: a population-based national study. Dig Dis Sci . 2019;64:3602–3609.
Sheriff MZ, Mansoor E, Luther J, et al. Opportunistic infections are more prevalent in Crohn's disease and ulcerative colitis: a large population-based study. Inflamm Bowel Dis . 2020;26:291–300.
Hill E, Abboud H, Briggs FBS. Prevalence of asthma in multiple sclerosis: a United States population-based study. Mult Scler Relat Disord . 2019;28:69–74.
Eland IA, Sundström A, Velo GP, et al. Antihypertensive medication and the risk of acute pancreatitis: the European case-control study on drug-induced acute pancreatitis (EDIP). Scand J Gastroenterol . 2006;41:1484–1490.
Kuoppala J, Enlund H, Pulkkinen J, et al. ACE inhibitors and the risk of acute pancreatitis—a population-based case-control study. Pharmacoepidemiol Drug Saf . 2017;26:853–857.
Griesbacher T. Kallikrein-kinin system in acute pancreatitis: potential of B(2)-bradykinin antagonists and kallikrein inhibitors. Pharmacology . 2000;60:113–120.
Mahamid M, Watad A, Bragazzi NL, et al. Chronic use of statins and their effect on prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis. Front Pharmacol . 2018;9:704.
Hadi YB, Naqvi SF, Abdelqader A, et al. Reduced risk of post ERCP pancreatitis in statin users. BMC Gastroenterol . 2020;20:125.
Martínez-Moneo E, Cárdenas-Jaén K, Fernández-Laso AB, et al. Statins chronic use is associated to decreased post-ERCP acute pancreatitis incidence. Pancreatology . 2017;17:2.
Poropat G, Archibugi L, Korpela T, et al. Statin use is not associated with an increased risk of acute pancreatitis—a meta-analysis of observational studies. United European Gastroenterol J . 2018;6:1206–1214.
Hakuta R, Nakai Y, Hamada T, et al. Regular statin use and incidence of postendoscopic retrograde cholangiopancreatography pancreatitis. J Clin Gastroenterol . 2020;54:905–910.
Badalov N, Baradarian R, Iswara K, et al. Drug-induced acute pancreatitis: an evidence-based review. Clin Gastroenterol Hepatol . 2007;5:648–661; quiz 644.
Singh S, Loke YK. Statins and pancreatitis: a systematic review of observational studies and spontaneous case reports. Drug Saf . 2006;29:1123–1132.
Floyd A, Pedersen L, Nielsen GL, et al. Secular trends in incidence and 30-day case fatality of acute pancreatitis in North Jutland County, Denmark: a register-based study from 1981–2000. Scand J Gastroenterol . 2002;37:1461–1465.